• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Defence Therapeutics Inc (OP:DTCFF)

    0.2760 -0.0409 (-12.91%)
    Delayed Quote Updated: 11:47 AM EDT, Oct 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Defence Therapeutics Inc

    News headline image
    Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
    Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
    From Virtual Investor Conferences; Defence Therapeutics
    Via GlobeNewswire
    News headline image
    Life Sciences Virtual Investor Forum Agenda Announced for December 11th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
    (November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in 
    Via PressReach
    Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
    EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
    (November 7, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge 
    Via PressReach
    Topics Intellectual Property
    Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
    EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
    (October 18, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the 
    Via PressReach
    News headline image
    Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
    Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
    Via PressReach
    News headline image
    Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
    Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
    Via PressReach
    News headline image
    Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
    (October 10, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the 
    Via PressReach
    News headline image
    Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
    (September 25, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the 
    Via PressReach
    News headline image
    BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
    Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics... 
    Via Newsfile
    News headline image
    BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
    Vancouver, British Columbia--(Newsfile Corp. - May 4, 2023) - On FOX Business News broadcast on Sunday, May 7 at 5:30... 
    Via Newsfile
    Topics Supply Chain
    News headline image
    Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
    Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
    Via Newsfile
    Topics Death Intellectual Property
    News headline image
    Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
    Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
    Via Newsfile
    News headline image
    Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
    Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
    Via Newsfile
    Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma; Puts Second Catalyst In Play (OTCMKTS: DTCFF)
    Via AB Newswire
    Defence Therapeutics ACCUM™ Technology Can Be A Treatment Game-Changer And Beating Breast Cancer Is In Its Crosshairs (OTCMKTS: DTCFF)
    Via AB Newswire
    Defence Therapeutics Draws Interest As Planned Phase 1 Breast Cancer Drug Trial Nears; Posts 116% Gain Since May (OTCMKTS: DTCFF)
    Via AB Newswire
    Defence Therapeutics Is Advancing Next-Generation Vaccine Technology To Beat Cancers And Virus, Even After They Mutate (OTCMKTS: DTCFF)
    Via AB Newswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.